A prospective evaluation of degranulation assays in the rapid diagnosis of familial hemophagocytic syndromes

Blood

Volumn 119, Issue 12, 2012, Pages 2754-2763

  Bryceson, Yenan T ^a   Pende, Daniela ^b   Maul Pavicic, Andrea ^c   Gilmour, Kimberly C ^d   Ufheil, Heike ^c   Vraetz, Thomas ^c   Chiang, Samuel C ^a   Marcenaro, Stefania ^b   Meazza, Raffaella ^b   Bondzio, Ilka ^c   Walshe, Denise ^d   Janka, Gritta ^e   Lehmberg, Kai ^e   Beutel, Karin ^f   Stadt, Udo Zur ^e   Binder, Nadine ^c   Arico, Maurizio ^g   Moretta, Lorenzo ^h   Henter, Jan Inge ^a   Ehl, Stephan ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF FREIBURG   (Germany)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^g UNIVERSITY OF FLORENCE   (Italy)

^h G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; PERFORIN; SIGNALING LYMPHOCYTE ACTIVATION MOLECULE ASSOCIATED PROTEIN; X LINKED INHIBITOR OF APOPTOSIS;

ARTICLE; CHEDIAK HIGASHI SYNDROME; CYTOTOXIC T LYMPHOCYTE; DEGRANULATION; EXOCYTOSIS; GENETIC DISORDER; GRISCELLI SYNDROME; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DIAGNOSIS; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; UPREGULATION;

EID: 84858812138     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-08-374199     Document Type: Article

References (48)

1. Janka GE. Hemophagocytic syndromes. Blood Rev. 2007;21(5):245-253. (Pubitemid 47212601)
2. Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6(1):137-154.
3. Arceci RJ. When T cells and macrophages do not talk: the hemophagocytic syndromes. Curr Opin Hematol. 2008;15(4):359-367.
4. Stepp SE, Dufourcq-Lagelouse R, Le Deist F, et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science. 1999;286(5446):1957- 1959. (Pubitemid 129515904)
5. Feldmann J, Callebaut I, Raposo G, et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell. 2003; 115(4):461-473. (Pubitemid 37456808)
6. zur Stadt U, Schmidt S, Kasper B, et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet. 2005;14(6):827-834. (Pubitemid 40403278)
7. zur Stadt U, Rohr J, Seifert W, et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet. 2009; 85(4):482-492.
8. Côte M, Menager MM, Burgess A, et al. Munc18-2 deficiency causes familial hemophagocytic lymphohistiocytosis type 5 and impairs cytotoxic granule exocytosis in patient NK cells. J Clin Invest. 2009; 119(12):3765-3773.
9. de Saint Basile G, Menasche G, Fischer A. Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules. Nat Rev Immunol. 2010; 10(8):568-579.
10. Cetica V, Pende D, Griffiths GM, Arico M. Molecular basis of familial hemophagocytic lymphohistiocytosis. Haematologica. 2010;95(4):538-541.
11. Ménasché G, Pastural E, Feldmann J, et al. Mutations in RAB27A cause Griscelli syndrome associated with haemophagocytic syndrome. Nat Genet. 2000;25(2):173-176. (Pubitemid 30394987)
12. Barbosa MD, Nguyen QA, Tchernev VT, et al. Identification of the homologous beige and Chediak- Higashi syndrome genes. Nature. 1996; 382(6588):262-265. (Pubitemid 26251362)
13. Roder JC, Haliotis T, Klein M, et al. A new immunodeficiency disorder in humans involving NK cells. Nature. 1980;284(5756):553-555. (Pubitemid 10070335)
14. Wood SM, Meeths M, Chiang SC, et al. Different NK cell-activating receptors preferentially recruit Rab27a or Munc13-4 to perforin-containing granules for cytotoxicity. Blood. 2009;114(19):4117- 4127.
15. Coffey AJ, Brooksbank RA, Brandau O, et al. Host response to EBV infection in X-linked lymphoproliferative disease results from mutations in an SH2-domain encoding gene. Nat Genet. 1998; 20(2):129-135. (Pubitemid 28455444)
16. Rigaud S, Fondaneche MC, Lambert N, et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature. 2006; 444(7115):110-114. (Pubitemid 44684766)
17. Booth C, Gilmour KC, Veys P, et al. X-linked lymphoproliferative disease due to SAP/SH2D1A deficiency: a multicenter study on the manifestations, management and outcome of the disease. Blood. 2011;117(1):53-62.
18. Marsh RA, Madden L, Kitchen BJ, et al. XIAP deficiency: a unique primary immunodeficiency best classified as X-linked familial hemophagocytic lymphohistiocytosis and not as X-linked lymphoproliferative disease. Blood. 2010;116(7): 1079-1082.
19. Janka G, Imashuku S, Elinder G, Schneider M, Henter JI. Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998;12(2):435-444. (Pubitemid 28175891)
20. Ravelli A. Macrophage activation syndrome. Curr Opin Rheumatol. 2002;14(5):548-552. (Pubitemid 34953793)
21. Maakaroun NR, Moanna A, Jacob JT, Albrecht H. Viral infections associated with haemophagocytic syndrome. Rev Med Virol. 2010;20(2):93-105.
22. Jordan MB, Filipovich AH. Hematopoietic cell transplantation for hemophagocytic lymphohistiocytosis: a journey of a thousand miles begins with a single (big) step. Bone Marrow Transplant. 2008;42(7):433-437.
23. Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131. (Pubitemid 44958267)
24. Johnson TS, Villanueva J, Filipovich AH, Marsh RA, Bleesing JJ. Contemporary diagnostic methods for hemophagocytic lymphohistiocytic disorders. J Immunol Methods. 2011; 364(1-2):1-13.
25. Horne A, Zheng C, Lorenz I, et al. Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. Br J Haematol. 2005;129(5): 658-666. (Pubitemid 40825828)
26. Kogawa K, Lee SM, Villanueva J, Marmer D, Sumegi J, Filipovich AH. Perforin expression in cytotoxic lymphocytes from patients with hemophagocytic lymphohistiocytosis and their family members. Blood. 2002;99(1):61-66.
27. Shinozaki K, Kanegane H, Matsukura H, et al. Activation-dependent T cell expression of the X-linked lymphoproliferative disease gene product SLAM-associated protein and its assessment for patient detection. Int Immunol. 2002;14(10): 1215-1223. (Pubitemid 35175228)
28. Marsh RA, Villanueva J, Zhang K, et al. A rapid flow cytometric screening test for X-linked lymphoproliferative disease due to XIAP deficiency. Cytometry B Clin Cytom. 2009;76(5):334-344.
29. Marcenaro S, Gallo F, Martini S, et al. Analysis of natural killer-cell function in familial hemophagocytic lymphohistiocytosis (FHL): defective CD107a surface expression heralds Munc13-4 defect and discriminates between genetic subtypes of the disease. Blood. 2006;108(7):2316- 2323.
30. Bryceson YT, Rudd E, Zheng C, et al. Defective cytotoxic lymphocyte degranulation in syntaxin-11 deficient familial hemophagocytic lymphohistiocytosis 4 (FHL4) patients. Blood. 2007;110(6):1906- 1915.
31. Enders A, Zieger B, Schwarz K, et al. Lethal hemophagocytic lymphohistiocytosis in Hermansky- Pudlak syndrome type II. Blood. 2006;108(1):81- 87.
32. Peters PJ, Borst J, Oorschot V, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991;173(5):1099-1109.
33. Bryceson YT, March ME, Barber DF, Ljunggren HG, Long EO. Cytolytic granule polarization and degranulation controlled by different receptors in resting NK cells. J Exp Med. 2005;202(7):1001- 1012.
34. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281(1-2): 65-78. (Pubitemid 37324571)
35. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods. 2004; 294(1-2):15-22. (Pubitemid 39626587)
36. Bryceson YT, Ljunggren HG, Long EO. Minimal requirement for induction of natural cytotoxicity and intersection of activation signals by inhibitory receptors. Blood. 2009;114(13):2657-2666.
37. Wheeler RD, Cale CM, Cetica V, Arico M, Gilmour KC. A novel assay for investigation of suspected familial haemophagocytic lymphohistiocytosis. Br J Haematol. 2010;150:727-30.
38. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2011.
39. Robin X, Turck N, Hainard A, et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves. BMC Bioinformatics. 2011;12:77.
40. Rudd E, Bryceson YT, Zheng C, et al. Spectrum, and clinical and functional implications of UNC13D mutations in familial hemophagocytic lymphohistiocytosis. J Med Genet. 2008;45(3): 134-141. (Pubitemid 351373741)
41. Meeths M, Entesarian M, Al-Herz W, et al. Spectrum of clinical presentations in familial hemophagocytic lymphohistiocytosis (FHL) type 5 patients with mutations in STXBP2. Blood. 2010; 116(15):2635-2643.
42. Rohr J, Beutel K, Maul-Pavicic A, et al. Atypical familial hemophagocytic lymphohistiocytosis due to mutations in UNC13D and STXBP2 overlaps with primary immunodeficiency diseases. Haematologica. 2010;95(12):2080-2087.
43. Santoro A, Cannella S, Trizzino A, et al. Mutations affecting mRNA splicing are the most common molecular defect in patients with familial hemophagocytic lymphohistiocytosis type 3. Haematologica. 2008;93(7):1086-1090. (Pubitemid 351957028)
44. Meeths M, Chiang SC, Wood SM, et al. Familial hemophagocytic lymphohistiocytosis type 3 (FHL3) caused by deep intronic mutation and inversion in UNC13D. Blood. 2011;118:5783-5793.
45. Jessen B, Maul-Pavicic A, Ufheil H, et al. Subtle differences in CTL cytotoxicity determine susceptibility to hemophagocytic lymphohistiocytosis in mice and humans with Chediak-Higashi syndrome. Blood. 2011;118:4620-4629.
46. Sieni E, Cetica V, Santoro A, et al. Genotypephenotype study of familial haemophagocytic lymphohistiocytosis type 3. J Med Genet. 2011; 48(5):343-352.
47. Marsh RA, Satake N, Biroschak J, et al. STX11 mutations and clinical phenotypes of familial hemophagocytic lymphohistiocytosis in North America. Pediatr Blood Cancer. 2010;55(1):134-140.
48. Macartney CA, Weitzman S, Wood SM, et al. Unusual functional manifestations of a novel STX11 frameshift mutation in two infants with familial hemophagocytic lymphohistiocytosis type 4 (FHL4). Pediatr Blood Cancer. 2011;56(4):654-657.